Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
INCHEON, Korea, February 24, 2025--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that PYZCHIVA ® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United ...
Ustekinumab is a human interleukin-12 and -23 antagonist indicated for multiple chronic inflammatory diseases. A biosimilar is a biological product that is approved based on data demonstrating that ...
The approval was based on a totality of evidence, including data from a phase 3 study (ClinicalTrials.gov Identifier: NCT04967508) that compared the efficacy and safety of Pyzchiva to the reference ...
(RTTNews) - Sandoz Group AG (SDZNY), a Swiss maker of generic and biosimilar medicines, announced Monday that the US Food and Drug Administration has approved biosimilar Pyzchiva (ustekinumab-ttwe), ...
Please provide your email address to receive an email when new articles are posted on . Pyzchiva, an ustekinumab biosimilar, is approved for all indications of the reference medicine, including ...
(RTTNews) - Sandoz Group AG (SDZNY.OB), a Swiss company that focuses on generic pharmaceuticals and biosimilars, today announced the approval of Pyzchiva. The FDA has granted approval to Pyzchiva, a ...
Sandoz is releasing Pyzchiva (ustekinumab) across Europe. Pyzchiva is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for ...
Sandoz (OTCQX:SDZNY) Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has ...
PYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the settlement and licensing agreement with Janssen Biotech Inc. PYZCHIVA will be commercialized by Sandoz ...
Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results